The Efemoral Vascular Scaffold System (EVSS) for the Treatment of Patients With Symptomatic Peripheral Vascular Disease From Stenosis or Occlusion of the Femoropopliteal Artery

Exclusion Criteria

• •Hemoglobin \<9.0 g/dL
• •WBC \<3,000 cells/mm3
• •Platelet count \<80,000 cells/mm3 or \>700,000 cells/mm3
• •Acute or chronic renal dysfunction with creatinine \>2.5 mg/dl (176 µmol/L)
• •Severe liver impairment as defined by total bilirubin ≥3 mg/dl or two times increase over the normal level of SGOT or SGPT
• •A known hypersensitivity or contraindication to aspirin, heparin, bivalirudin, ticagrelor or sirolimus, or with contrast sensitivity for which the patient cannot be adequately pre-medicated
• •Patient requires a planned procedure that would necessitate discontinuation of antiplatelet therapy
• •Patient is unable to walk
• •Patient has undergone a percutaneous vascular intervention \<30 days prior to the planned index procedure
• •Patient is maintained on chronic hemodialysis
• •Patient has uncontrolled diabetes mellitus (HbA1c ≥7.0%).
• •Patient has had a myocardial infarction within the previous 30 days of the planned index procedure
• •Patient has had a stroke within the previous 30 days of the planned index procedure and/or has deficits from a prior stroke that limits the patient's ability to walk
• •Patient has unstable angina defined as rest angina with ECG changes
• •Patient has a local groin or acute systemic infection that has not been treated successfully or is currently under treatment
• •Patient has acute thrombophlebitis, deep vein thrombosis or chronic venous insufficiency in either extremity
• •Patient has other medical illnesses (e.g., cancer, congestive cardiomyopathy, etc.) that may cause the patient to be non-compliant with protocol requirements, confound the data interpretation or will prevent completion of all required follow up assessments through 36 months
• •Patient is currently participating in an investigational drug, biologic, or device study that has not completed the primary endpoint or that clinically interferes with the current study endpoints
• •Patient has ischemic or neuropathic ulcers on either foot
• •Patient has undergone minor or major amputation of either lower extremity
• •Patient is part of a vulnerable population who, in the judgment of the Investigator, is unable to give informed consent
• •Target extremity with an angiographically significant (\>50% DS) lesion located distal to the target lesion that requires treatment at the time of the index procedure or by a staged procedure
• •Acute arterial ischemia of the target extremity
• •Target extremity has been previously treated with open surgical revascularization (bypass or endarterectomy)
• •Target vessel has been previously treated with stent, laser, atherectomy, surgical bypass, or endarterectomy
• •Total occlusion (100% DS) of the ipsilateral inflow artery
• •Angiographic evidence of thrombus in the target vessel
• •The target lesion requires treatment with a device other than percutaneous transluminal balloon angioplasty (PTA) \[e.g., orbital atherectomy, directional atherectomy, excimer laser, rotational atherectomy, cryoplasty, etc.\]
• •Target lesion is within or adjacent to an aneurysm
• •Patient has angiographic evidence of thromboembolism or atheroembolism from treatment of an ipsilateral iliac lesion or from crossing or pre-dilating the target lesion
• •Target lesion has moderate-to-severe calcification
• •Target lesion with \> 30% residual stenosis following pre-dilatation